OasisLMS

Co-chaired by esteemed experts Mouaz Al-Mallah, MD, MSc and Panithaya Chareonthaitawee, MD, a series of two webinars will be offered on January 23, 2025, 6:30-8:00 PM ET and April 15, 2025, 6:30-8:00 PM ET. Each webinar will feature an in-depth review of a spectrum of clinical cases across key patient populations with a unique set of faculty expert panelists to broaden your knowledge and deepen your understanding of these new tracers. 

The April 15 webinar includes faculty Timothy Bateman, MD; James Case, PhD; Rob deKemp, PhD; Marcelo Di Carli, MD; and Prem Soman, MD, PhD.

Registrants will have access to the recording of the webinar for OnDemand self-guided learning.

• Educate imaging physicians and technologists on acquisition, interpretation, and reporting of F-18 cardiac PET perfusion tracers.
• Increase the reader’s skill through a comprehensive case study review of clinically relevant cases with leading PET and F-18 flurpiridaz experts.
• Establish a methodical approach to reviewing image findings of F-18 flurpiridaz images.
• Instruct learners on the elements of a F-18 flurpiridaz imaging report.

• Describe acquisition protocols, interpretation, and reporting requirements of F-18 cardiac PET perfusion tracers
• Identify the physiological uptake patterns, incidental findings, and normal variants for F-18 tracers and differences from existing cardiac PET tracers
• Explain methodical approaches to review image findings of F-18 flurpiridaz images
• Demonstrate increased skill through a comprehensive case study review of clinically relevant cases with leading PET and F-18 flurpiridaz experts

PET imaging, especially PET MPI with assessment of myocardial blood flow, is the future of nuclear cardiology in the evolving multimodality environment. It offers significant advantages over SPECT imaging. F-18 tracers provide opportunities for users to start using cardiac PET MPI. The availability of a unit dose eliminates the cost of a rubidium-82 generator or installation of an N-13 ammonia cyclotron for nuclear cardiology labs with limited PET MPI studies.  For those using rubidium-28 and/or N-13 ammonia, the unit dose option provides important “fill-in” opportunities. Also, PET MPI with/without blood flow has a favorable reimbursement profile. 

Flurpiridaz is an F-18-based tracer and the first new tracer in several decades.No detailed F-18 flurpiridaz case-based learning currently exists; this series of webinars and self-directed case-based learning activity aims to serve as a resource for practitioners interested in incorporating flurpiridaz into their laboratories. 

Physicians: The American Society of Nuclear Cardiology designates this internet live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

As an accredited provider of the Accreditation Council for Continuing Medical Education (ACCME), The American Society of Nuclear Cardiology (ASNC) adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.  In compliance with these standards, it is ASNC’s policy to ensure balance, independence, objectivity, and scientific merit in all of its educational activities through the disclosure of all financial relationships with ineligible companies and mitigation of conflicts of interest.  The financial interest or relationships requiring disclosure are outlined in ASNC’s CME Conflict of Interest Policy.  All persons who influenced the content of this activity are required to disclose all financial relationships.  The American Society of Nuclear Cardiology has reviewed these disclosures and mitigated or managed all identified conflicts of interest through a peer review process.

The following faculty, reviewers and ASNC staff who were involved in the planning and development of this activity reported no financial relationships:
Renée Bullock-Palmer, MD (Education Reviewer)
Linda Giering, PhD (ASNC Staff)
Dawn Edgerton (ASNC Staff)

Faculty who were involved in the planning and development of this activity reported the following financial relationships:
Mouaz Al-Mallah, MD, MSc, MASNC - Research Grants (Siemens; GE Healthcare); Consultant (Jubilant Radiopharma; MedTrace; Phillips; Pfizer)
Panithaya Chareonthaitawee, MD - Consultant (GE Healthcare); Royalties (UpToDate)
Timothy Bateman, MD, MASNC - Ownership – CVIT; Consultant – GEHC, Synektik; Research grants – Bracco, GEHC, Spectrum Dynamics
James Case, PhD, MASNC - Research grants – Bracco, GE, Spectrum Dynamics; Consultant – GE; Owner - CVIT
Marcelo Di Carli, MD, MASNC - Research Grants (Amgen (institutional); Gilead Sciences); Consultant (Bitterroot Bio; IBA; MedTrace; Sanofi; Sun Pharma; Valo Health) 
Robert deKemp, PhD, MASNC - Royalty/research grant – Jubilant DraxImage; License revenue – INVIA Medical Solutions
Prem Soman, MD, PhD, MASNC - Research grant – Pfizer; Consulting – Alnylam, Spectrum Dynamics, Eidos, Pfizer 

This activity is supported by an unrestricted educational grant from GE HealthCare.